Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Braftovi and Mektovi in recurrent BRAF V600-mutated high-grade brain tumors
NCT03973918Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, binimetinib in glioma, anaplastic astrocytoma (AA), anaplastic pleomorphic xanthoastrocytoma (APXA), Gliosarcoma (GS), glioblastoma (GBM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2019; status: terminated.
02
Drugs
encorafenibbinimetinib
03
Conditions
gliomaanaplastic astrocytoma (AA)anaplastic pleomorphic xanthoastrocytoma (APXA)Gliosarcoma (GS)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03973918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03973918.